Reilly Financial Advisors LLC raised its stake in Pfizer, Inc. (NYSE:PFE) by 0.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 310,962 shares of the biopharmaceutical company’s stock after buying an additional 2,323 shares during the period. Reilly Financial Advisors LLC’s holdings in Pfizer were worth $10,445,000 as of its most recent filing with the SEC.
Other large investors have also made changes to their positions in the company. Guggenheim Capital LLC increased its stake in shares of Pfizer by 16.9% in the fourth quarter. Guggenheim Capital LLC now owns 2,995,589 shares of the biopharmaceutical company’s stock valued at $97,298,000 after buying an additional 433,782 shares during the last quarter. AQR Capital Management LLC increased its stake in shares of Pfizer by 5.9% in the fourth quarter. AQR Capital Management LLC now owns 10,312,918 shares of the biopharmaceutical company’s stock valued at $334,964,000 after buying an additional 573,111 shares during the last quarter. HCR Wealth Advisors acquired a new stake in shares of Pfizer during the fourth quarter valued at $567,000. Ladenburg Thalmann Financial Services Inc. increased its stake in shares of Pfizer by 1.1% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 651,910 shares of the biopharmaceutical company’s stock valued at $21,231,000 after buying an additional 6,830 shares during the last quarter. Finally, Denver Investment Advisors LLC increased its stake in shares of Pfizer by 4.9% in the fourth quarter. Denver Investment Advisors LLC now owns 500,063 shares of the biopharmaceutical company’s stock valued at $16,242,000 after buying an additional 23,268 shares during the last quarter. 69.94% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Pfizer, Inc. (NYSE:PFE) traded down 0.51% on Thursday, hitting $33.19. 4,021,964 shares of the stock traded hands. The firm’s 50-day moving average is $33.35 and its 200 day moving average is $33.37. The firm has a market cap of $197.39 billion, a P/E ratio of 24.28 and a beta of 1.00. Pfizer, Inc. has a 12-month low of $29.83 and a 12-month high of $35.38.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. The business had revenue of $12.90 billion during the quarter, compared to analyst estimates of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The business’s revenue was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.64 earnings per share. Equities research analysts forecast that Pfizer, Inc. will post $2.56 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Friday, August 4th will be paid a $0.32 dividend. The ex-dividend date of this dividend is Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.84%. Pfizer’s dividend payout ratio (DPR) is presently 94.12%.
TRADEMARK VIOLATION NOTICE: This piece was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://stocknewstimes.com/2017/08/17/reilly-financial-advisors-llc-acquires-2323-shares-of-pfizer-inc-pfe.html.
PFE has been the topic of several recent research reports. Sanford C. Bernstein reaffirmed a “buy” rating and set a $35.00 target price on shares of Pfizer in a research note on Monday, April 24th. BMO Capital Markets reaffirmed a “hold” rating and set a $33.00 target price on shares of Pfizer in a research note on Thursday, April 27th. Barclays PLC reaffirmed a “buy” rating and set a $38.00 target price on shares of Pfizer in a research note on Wednesday, May 3rd. Citigroup Inc. downgraded shares of Pfizer from a “neutral” rating to a “sell” rating and cut their target price for the stock from $38.00 to $31.00 in a research note on Tuesday, May 16th. Finally, ValuEngine downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $37.61.
In other Pfizer news, CEO Ian C. Read sold 96,950 shares of Pfizer stock in a transaction on Friday, August 4th. The shares were sold at an average price of $34.00, for a total value of $3,296,300.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Alexander R. Mackenzie sold 15,000 shares of Pfizer stock in a transaction on Monday, August 7th. The stock was sold at an average price of $33.50, for a total transaction of $502,500.00. Following the completion of the transaction, the insider now directly owns 151,474 shares of the company’s stock, valued at approximately $5,074,379. The disclosure for this sale can be found here. 0.06% of the stock is currently owned by insiders.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
